tiprankstipranks
Mannatech Inc. (MTEX)
NASDAQ:MTEX
US Market
Want to see MTEX full AI Analyst Report?

Mannatech (MTEX) AI Stock Analysis

77 Followers

Top Page

MTEX

Mannatech

(NASDAQ:MTEX)

Select Model
Select Model
Select Model
Underperform 40 (OpenAI - 5.2)
Rating:40Underperform
Price Target:
$4.50
▼(-43.40% Downside)
Action:ReiteratedDate:04/25/26
The score is driven primarily by weak financial performance (multi-year revenue decline, 2025 loss, negative equity, and renewed cash burn) and negative corporate developments (Nasdaq noncompliance/delisting risk and delayed 10-K amid going-concern review). Technicals also show a persistent downtrend, with oversold signals providing only limited offset; valuation is difficult to support given negative earnings.
Positive Factors
High gross margins
Sustained gross margins near 75% indicate durable product economics and pricing power in core supplements. High unit margins provide long-term flexibility to absorb marketing or SG&A while still enabling path to profitability if distribution efficiency or overheads are improved.
Negative Factors
Multi-year revenue decline
A steady revenue decline over several years indicates weakening market penetration or lower associate activity. Structural top-line erosion constrains operating leverage and makes restoring profitability harder, requiring sustained improvements in distribution, product mix or new market expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins near 75% indicate durable product economics and pricing power in core supplements. High unit margins provide long-term flexibility to absorb marketing or SG&A while still enabling path to profitability if distribution efficiency or overheads are improved.
Read all positive factors

Mannatech (MTEX) vs. SPDR S&P 500 ETF (SPY)

Mannatech Business Overview & Revenue Model

Company Description
Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its p...
How the Company Makes Money
Mannatech makes money primarily by selling its health and wellness products to end customers through a direct-selling distribution network. The company recognizes revenue from product sales (net of discounts/returns/allowances, where applicable) w...

Mannatech Financial Statement Overview

Summary
Fundamentals are high risk: revenue has declined for multiple years, 2025 swung to a sizable net loss, equity turned negative (stockholders’ deficit), and operating/free cash flow returned to meaningful negative levels in 2025. Strong gross margins are a positive, but they have not translated into consistent profitability or cash generation.
Income Statement
33
Negative
Balance Sheet
26
Negative
Cash Flow
28
Negative
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue108.04M117.87M131.96M137.21M159.76M
Gross Profit80.96M91.46M102.86M102.52M125.61M
EBITDA-426.00K5.55M498.00K3.02M10.61M
Net Income-15.21M2.49M-2.24M-4.49M9.84M
Balance Sheet
Total Assets29.99M36.06M41.21M49.13M59.63M
Cash, Cash Equivalents and Short-Term Investments6.18M11.40M7.73M13.78M24.18M
Total Debt7.36M6.69M5.71M6.21M1.83M
Total Liabilities35.22M27.44M30.72M34.95M35.21M
Stockholders Equity-5.22M8.61M10.48M14.18M24.41M
Cash Flow
Free Cash Flow-4.32M1.96M-3.12M-3.66M10.12M
Operating Cash Flow-2.96M2.26M-2.37M-2.60M10.77M
Investing Cash Flow-1.35M-285.00K-747.00K-1.06M-650.00K
Financing Cash Flow-561.00K1.96M-1.90M-4.33M-9.29M

Mannatech Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.95
Price Trends
50DMA
6.57
Negative
100DMA
7.45
Negative
200DMA
8.15
Negative
Market Momentum
MACD
-0.44
Positive
RSI
39.73
Neutral
STOCH
12.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTEX, the sentiment is Negative. The current price of 7.95 is above the 20-day moving average (MA) of 6.07, above the 50-day MA of 6.57, and below the 200-day MA of 8.15, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 39.73 is Neutral, neither overbought nor oversold. The STOCH value of 12.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTEX.

Mannatech Risk Analysis

Mannatech disclosed 39 risk factors in its most recent earnings report. Mannatech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Mannatech Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$318.04M-64.1815.38%-4.74%-11.26%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
55
Neutral
$351.12M2.9620.36%2.39%-14.26%
52
Neutral
$1.02B-3.02-2.50%3.51%-3.36%-145.55%
48
Neutral
$104.15M-5.47-15.42%-10.01%68.05%
47
Neutral
$9.10M16.79%
40
Underperform
$8.61M-1.03-19.54%-8.34%-705.66%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MTEX
Mannatech
4.46
-5.99
-57.32%
NUS
Nu Skin
7.14
0.97
15.66%
EPC
Edgewell Personal Care
21.75
-7.97
-26.81%
SKIN
Beauty Health
0.80
-0.19
-18.97%
EWCZ
European Wax Center
5.80
2.68
85.90%
TKLF
Yoshitsu Co. Ltd. Sponsored ADR
2.15
-1.30
-37.68%

Mannatech Corporate Events

Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Mannatech Faces Nasdaq Noncompliance and Potential Delisting Risk
Negative
Apr 24, 2026
On April 20, 2026, Mannatech disclosed that it had received a notice from Nasdaq stating the company was no longer in compliance with the exchange’s minimum stockholders’ equity requirement of $2.5 million, after reporting a stockholde...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Mannatech Delays 10-K Filing Amid Going-Concern Review
Negative
Apr 2, 2026
On April 1, 2026, Mannatech, Incorporated announced it had filed a Form 12b-25 with the U.S. Securities and Exchange Commission, notifying regulators of a delayed filing of its Form 10-K for the fiscal year ended December 31, 2025. The annual repo...
Business Operations and StrategyExecutive/Board Changes
Mannatech Names Interim CFO Amid Leadership Transition
Neutral
Mar 24, 2026
On March 19, 2026, Mannatech, Incorporated decided by mutual agreement not to renew the employment contract of Chief Financial Officer James Clavijo, whose agreement is set to expire on June 30, 2026, and he will receive three months of base salar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2026